Cargando…

Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy

In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and thei...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chun-Hou, Chen, Peir-Rorg, Lue, Kun-Han, Hsieh, Tsung-Cheng, Chou, Yu-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464994/
https://www.ncbi.nlm.nih.gov/pubmed/34575713
http://dx.doi.org/10.3390/jpm11090936
_version_ 1784572757601681408
author Huang, Chun-Hou
Chen, Peir-Rorg
Lue, Kun-Han
Hsieh, Tsung-Cheng
Chou, Yu-Fu
author_facet Huang, Chun-Hou
Chen, Peir-Rorg
Lue, Kun-Han
Hsieh, Tsung-Cheng
Chou, Yu-Fu
author_sort Huang, Chun-Hou
collection PubMed
description In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and their survival outcomes. We retrospectively enrolled 175 patients with OSCC undergoing adjuvant CRT between 2011 and 2018, who were divided into groups with (n = 112) and without (n = 63) sarcopenia. Logistic regression analysis and Cox proportional hazards models were used to determine prognostic factors for CRT-related toxicity, three-year overall survival (OS), and disease-free survival (DFS). Sarcopenia and high PLR were independently associated with CRT-induced anemia (CIA); advanced tumor stage was related to poor three-year OS. CRT and survival did not differ by mFI-5 and NLR. Our results indicate that sarcopenia and high PLR are significant predictors of adjuvant CRT, increasing toxicity outcomes and indicating worse short-term OS. Accurately identifying sarcopenia and high PLR in patients with OSCC is critical to help better select candidates for adjuvant CRT to improve their outcomes.
format Online
Article
Text
id pubmed-8464994
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84649942021-09-27 Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy Huang, Chun-Hou Chen, Peir-Rorg Lue, Kun-Han Hsieh, Tsung-Cheng Chou, Yu-Fu J Pers Med Article In this study, we aimed to evaluate the prognostic impact of sarcopenia, five-item modified frailty index (mFI-5), neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR) in patients with oral cavity squamous cell carcinoma (OSCC) treated with adjuvant chemoradiotherapy (CRT) and their survival outcomes. We retrospectively enrolled 175 patients with OSCC undergoing adjuvant CRT between 2011 and 2018, who were divided into groups with (n = 112) and without (n = 63) sarcopenia. Logistic regression analysis and Cox proportional hazards models were used to determine prognostic factors for CRT-related toxicity, three-year overall survival (OS), and disease-free survival (DFS). Sarcopenia and high PLR were independently associated with CRT-induced anemia (CIA); advanced tumor stage was related to poor three-year OS. CRT and survival did not differ by mFI-5 and NLR. Our results indicate that sarcopenia and high PLR are significant predictors of adjuvant CRT, increasing toxicity outcomes and indicating worse short-term OS. Accurately identifying sarcopenia and high PLR in patients with OSCC is critical to help better select candidates for adjuvant CRT to improve their outcomes. MDPI 2021-09-19 /pmc/articles/PMC8464994/ /pubmed/34575713 http://dx.doi.org/10.3390/jpm11090936 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Huang, Chun-Hou
Chen, Peir-Rorg
Lue, Kun-Han
Hsieh, Tsung-Cheng
Chou, Yu-Fu
Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
title Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
title_full Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
title_fullStr Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
title_full_unstemmed Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
title_short Evaluation of Sarcopenia, Frailty, and Inflammation on Adverse Events and Survival Outcomes in Patients with Oral Cavity Squamous Cell Carcinoma under Adjuvant Chemoradiotherapy
title_sort evaluation of sarcopenia, frailty, and inflammation on adverse events and survival outcomes in patients with oral cavity squamous cell carcinoma under adjuvant chemoradiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464994/
https://www.ncbi.nlm.nih.gov/pubmed/34575713
http://dx.doi.org/10.3390/jpm11090936
work_keys_str_mv AT huangchunhou evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy
AT chenpeirrorg evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy
AT luekunhan evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy
AT hsiehtsungcheng evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy
AT chouyufu evaluationofsarcopeniafrailtyandinflammationonadverseeventsandsurvivaloutcomesinpatientswithoralcavitysquamouscellcarcinomaunderadjuvantchemoradiotherapy